May. 12 at 12:16 PM
$MDRX Veradigm advances GLP-1 real-world evidence generation with AI
Veradigm announced an advancement in the use of artificial intelligence to scale the generation of real-world evidence for GLP-1 receptor agonists, including semaglutide and tirzepatide. By applying AI to electronic health record deidentified data within the Veradigm Network, researchers can now surface rich, contextual insights-such as side effects, discontinuation reasons, and social determinants of health-that traditionally required intensive manual curation.